273 related articles for article (PubMed ID: 26482312)
21. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
22. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections.
Leonard SN; Rybak MJ
Pharmacotherapy; 2008 Apr; 28(4):458-68. PubMed ID: 18363530
[TBL] [Abstract][Full Text] [Related]
23. [Therapeutic impact of streptococcal and enterococcal bacteremia in hematology patients].
Ombandza-Moussa E; Schlegel L; Vekhoff A; Gerbal R; Marie JP; Bouvet A
Pathol Biol (Paris); 2002 Apr; 50(3):169-77. PubMed ID: 11980330
[TBL] [Abstract][Full Text] [Related]
24. Management of gram-positive coccal bacteremia and hemodialysis.
Fitzgibbons LN; Puls DL; Mackay K; Forrest GN
Am J Kidney Dis; 2011 Apr; 57(4):624-40. PubMed ID: 21333430
[TBL] [Abstract][Full Text] [Related]
25. Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy.
Chen CY; Tang JL; Hsueh PR; Yao M; Huang SY; Chen YC; Chen YC; Shen MC; Wang CH; Tsai W; Chang SC; Tien HF; Luh KT
J Formos Med Assoc; 2004 Jul; 103(7):526-32. PubMed ID: 15318274
[TBL] [Abstract][Full Text] [Related]
26. Daptomycin for Gram-positive Infections in Patients with Neutropenia: Clinical Experience from a European Outcomes Registry.
Keil F; Daikos GL; Skoutelis A; Dominguez JI; Pathan R; Hamed K
Adv Ther; 2015 Aug; 32(8):715-26. PubMed ID: 26239201
[TBL] [Abstract][Full Text] [Related]
27. [Role of daptomycin in the treatment of infections in patients with hematological malignancies].
Salavert M; Calabuig E
Med Clin (Barc); 2010 Dec; 135 Suppl 3():36-47. PubMed ID: 21477703
[TBL] [Abstract][Full Text] [Related]
28. Successful salvage treatment of native valve Enterococcus faecalis infective endocarditis with telavancin: two case reports.
Thompson MM; Hassoun A
Infect Dis (Lond); 2017 Jul; 49(7):540-544. PubMed ID: 28293958
[TBL] [Abstract][Full Text] [Related]
29. The clinical positioning of telavancin in Europe.
Masterton R; Cornaglia G; Courvalin P; Lode HM; Rello J; Torres A
Int J Antimicrob Agents; 2015 Mar; 45(3):213-20. PubMed ID: 25600892
[TBL] [Abstract][Full Text] [Related]
30. In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci.
Hope R; Chaudhry A; Adkin R; Livermore DM
Int J Antimicrob Agents; 2013 Mar; 41(3):213-7. PubMed ID: 23298432
[TBL] [Abstract][Full Text] [Related]
31. Linezolid for the treatment of infections caused by Gram-positive pathogens in China.
Lin DF; Zhang YY; Wu JF; Wang F; Zheng JC; Miao JZ; Zheng LY; Sheng RY; Zhou X; Shen HH; Ijzerman MM; Croos-Dabrera RV; Sheng W
Int J Antimicrob Agents; 2008 Sep; 32(3):241-9. PubMed ID: 18635341
[TBL] [Abstract][Full Text] [Related]
32. Outpatient treatment of osteomyelitis with telavancin.
Schroeder CP; Van Anglen LJ; Dretler RH; Adams JS; Prokesch RC; Luu Q; Krinsky AH
Int J Antimicrob Agents; 2017 Jul; 50(1):93-96. PubMed ID: 28456704
[TBL] [Abstract][Full Text] [Related]
33. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
[TBL] [Abstract][Full Text] [Related]
34. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
35. Bloodstream infections in neutropenic patients with cancer: differences between patients with haematological malignancies and solid tumours.
Marin M; Gudiol C; Ardanuy C; Garcia-Vidal C; Calvo M; Arnan M; Carratalà J
J Infect; 2014 Nov; 69(5):417-23. PubMed ID: 24960295
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer.
Jaksic B; Martinelli G; Perez-Oteyza J; Hartman CS; Leonard LB; Tack KJ
Clin Infect Dis; 2006 Mar; 42(5):597-607. PubMed ID: 16447103
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of novel glycopeptides versus vancomycin for the treatment of gram-positive bacterial infections including methicillin resistant Staphylococcus aureus: A systematic review and meta-analysis.
Jame W; Basgut B; Abdi A
PLoS One; 2021; 16(11):e0260539. PubMed ID: 34843561
[TBL] [Abstract][Full Text] [Related]
38. Telavancin: a new lipoglycopeptide for gram-positive infections.
Smith WJ; Drew RH
Drugs Today (Barc); 2009 Mar; 45(3):159-73. PubMed ID: 19436839
[TBL] [Abstract][Full Text] [Related]
39. Telavancin-associated acute kidney injury
.
Cavanaugh C; Moeckel GW; Perazella MA
Clin Nephrol; 2019 Mar; 91(3):187-191. PubMed ID: 30614441
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
